Ask AI

Staying the Course: Pharmacist Best Practices for Managing Adverse Events and Maintaining Therapy in EGFR-Mutated NSCLC

Gain expert insights on how to identify, prevent, and manage treatment-related adverse events associated with current and emerging therapies for patients with EGFR-mutated non-small-cell lung cancer through an APCE-certified live virtual symposium with an accompanying downloadable slideset and ClinicalThought commentary.

Share

Program Content

Activities

EGFR Therapy AE Management
Staying the Course: Pharmacist Best Practices for Managing Adverse Events and Maintaining Therapy in EGFR-Mutated NSCLC
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 28, 2026

Expires: November 27, 2026

Activities

NSCLC EGFR Inhibitor Management FAQs
Practical Frequently Asked Questions From Pharmacists on Managing Patients With EGFR-Targeted Therapy in NSCLC
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: June 12, 2026

Provided by

ProCE Banner

Provided by ProCE, LLC.

Supporters

Supported by an educational grant from Johnson & Johnson.

Johnson & Johnson